Bio‐evaluation of poly(lactic‐co‐glycolic) acid nanoparticles loaded with radiolabelled rifampicin
British Journal of Clinical Pharmacology · 2023-12 · 89 (12) · 3702-3714
DOI: 10.1111/bcp.15875 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 04.09.2023. Verfasst von Imran Rather und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, PGIMER, Chandigarh, India. Hauptthemen laut MEDLINE: Rifampin, Nanoparticles. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
Aims
The poly(lactic‐co‐glycolic) acid (PLGA) nanoparticles of tubercular drugs have been demonstrated to have a sustained release profile over 7 days. There is no information on the location or mode of release of these nanoparticles in living systems. Therefore, we have planned the study to explore the pharmacokinetics and biodistribution of PLGA rifampicin nanoparticles in healthy human volunteers. We aim to study the distribution pattern of PLGA‐loaded nano‐formulation of radiolabelled rifampicin in humans.
Methods
Rifampicin was labelled with 99m Tc by indirect method and nanoparticles were prepared by a single emulsion evaporation method. To investigate the pharmacokinetics and biodistribution of nanoparticles, a single dose of 450 mg of rifampicin was administered orally to healthy human volunteers divided into two different groups.
Results
Following a single oral dosage of the rifampicin nanoformulation, the pharmacokinetic (PK) parameters were significantly different between the nanoparticle and conventional groups: area under the concentration–time curve (AUC = 113.8 vs . 58.6; P < .001), mean residence time (MRT = 16.2 vs . 5.8; P < .01) and elimination rate constant (K e = 0.04 vs . 0.10; P < .05). Also, Single‐photon emission computed tomography/computed tomography (SPECT/CT) images revealed biodistribution of nanoparticles in the distal portions of the intestine, which is consistent with our dosimetry analysis.
Conclusions
Significant difference in PK parameters and biodistribution of nanoparticles in spleen and lymph nodes with maximum deposition were observed in the large intestine. The nanoparticle distribution pattern may be advantageous for the treatment of intestinal or lymph node tuberculosis (TB) and has the potential to result in a lower dose of rifampicin nanoformulation for the treatment of pulmonary TB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, PGIMER, Chandigarh, India.
- Department of Nuclear Medicine, PGIMER, Chandigarh, India.
- Department of Biochemistry, PGIMER, Chandigarh, India.
- Department of General Medicine, PGIMER, Chandigarh, India.
ORCID-Profile: Imran Rather, Nusrat Shafiq
Förderung
- Indian Council of Medical Research
Zitieren
APA
Rather, I., Shafiq, N., Shukla, J., Kaur, G., Pandey, S., Bhandari, R. K., Pandey, A. K., Mittal, B. R., Khuller, G. K., Sharma, N., & Malhotra, S. (2023). Bio‐evaluation of poly(lactic‐co‐glycolic) acid nanoparticles loaded with radiolabelled rifampicin. British Journal of Clinical Pharmacology, 89(12), 3702-3714. https://doi.org/10.1111/bcp.15875
Vancouver
Rather I, Shafiq N, Shukla J, Kaur G, Pandey S, Bhandari RK, et al. Bio‐evaluation of poly(lactic‐co‐glycolic) acid nanoparticles loaded with radiolabelled rifampicin. British Journal of Clinical Pharmacology. 2023;89(12):3702-3714. doi:10.1111/bcp.15875
BibTeX
@article{Rather2023,
author = {Rather, Imran and Shafiq, Nusrat and Shukla, Jaya and Kaur, Gurvinder and Pandey, Somit and Bhandari, Ritika Kondel and Pandey, Avaneesh Kumar and Mittal, B R and Khuller, G K and Sharma, Navneet and Malhotra, Samir},
title = {Bio‐evaluation of poly(lactic‐co‐glycolic) acid nanoparticles loaded with radiolabelled rifampicin},
journal = {British Journal of Clinical Pharmacology},
year = {2023},
volume = {89},
number = {12},
pages = {3702--3714},
doi = {10.1111/bcp.15875}
}
EUVIMED